drugset

Drugs / Etalanetug

Follow last change Jul 2026 re-read 9 days ago

Etalanetug

also known as E2814

Monoclonal antibody

Developed for: Alzheimer disease · early-onset autosomal dominant Alzheimer disease · familial Alzheimer disease
Investigated by: Eisai Inc. · Accelerating Medicines Partnership (AMP) · Alzheimer's Association · National Institute on Aging (NIA) · Washington University School of Medicine · Avid Radiopharmaceuticals
+3 more
· Eli Lilly and Company · Hoffmann-La Roche · Janssen, LP

Trials 5

today NCT06602258 · Ph 2 NCT05269394 · Ph 2/3 NCT04971733 · Ph 1/2 NCT04231513 · Ph 1 NCT01760005 · Ph 2/3

2013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 11 trial
Phase 1	NCT04231513	Dec 2019 → Mar 2023	—	Eisai Inc.	Completed	No outcome recorded
Phase 1/21 trial
Phase 1/2	NCT04971733	Jun 2021 → May 2024	Alzheimer disease	Eisai Inc.	Completed	No outcome recorded
Phase 21 trial
Phase 2	NCT06602258	Sep 2024 → Dec 2026 expected	Alzheimer disease	Eisai Inc.	Active not recruiting	No outcome recorded
Phase 2/32 trials
Phase 2/3	NCT05269394	Dec 2021 → Apr 2028 expected	early-onset autosomal dominant Alzheimer disease	Washington University School of Medicine	Active not recruiting	No outcome recorded
Phase 2/3	NCT01760005	Dec 2012 → Apr 2028 expected	familial Alzheimer disease	Washington University School of Medicine	Active not recruiting	No outcome recorded

News releases announcing trial results or a regulatory action · 6

Date	Issuer	Release
2026-07-14	Eisai Inc.	Results Eisai Presents Latest Findings Showed Etalanetug Reduced Alzheimer’s Disease Tau Tangle-Specific Plasma Biomarker MTBR-tau243 at Alzheimer’s Association International Conference® (AAIC®) 2026 Measuring the plasma eMTBR-tau243 biomarker may serve as a practical, less invasive method of capturing Alzheimer's disease-specific pathological changes and may play an important role in etalanetug’s future clinical development eisai.com ↗ Etalanetug reduced plasma eMTBR-tau243 by 78% at 3 months and by more than 90% at 9 months, indicating that plasma eMTBR-tau243 closely mirrored disease-related changes captured in CSF.
2025-12-02	Eisai Inc.	Results Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025 Etalanetug demonstrated reduction of eMTBR-tau243, a novel CSF and plasma biomarker that specifically reflects tau tangle pathology, in phase Ib/II study eisai.com ↗ TBR-tau243 was reduced by 78% at 3 months and over 90% at 9 months.
2025-09-17	Eisai Inc.	Regulatory Anti-MTBR (microtubule binding region) Tau Antibody Etalanetug Granted FDA Fast Track Designation eisai.com ↗ Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that etalanetug (development code: E2814), an investigational anti-MTBR (microtubule binding region) tau antibody, was granted Fast Track designation by the U.S. Food and Drug Administration (FDA).
2024-10-31	Eisai Inc.	Results EISAI PRESENTS LATEST CLINICAL FINDINGS SUGGESTING INHIBITION OF TAU PROPAGATION BY ANTI-MTBR TAU ANTIBODY E2814 AT THE 17TH CLINICAL TRIALS ON ALZHEIMER'S DISEASE CONFERENCE (CTAD) Eisai Initiates Phase II Clinical Study on Sporadic Early Alzheimer's Disease eisai.com ↗
2023-07-12	Eisai Inc.	Results EISAI TO PRESENT THE LATEST ALZHEIMER’S DISEASE PIPELINE AND RESEARCH, INCLUDING LECANEMAB AND ANTI-MTBR TAU ANTIBODY E2814, AT THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2023 eisai.com ↗ E2814: An Anti-Tau Therapy Engages its CNS Target and Affects the Downstream Tangle-Specific Biomarker MTBR-tau243 in Dominantly Inherited Alzheimer's Disease
2019-07-19	Eisai Inc.	Results EISAI PRESENTS DATA SHOWING QUANTIFICATION OF TAU MICROTUBULE BINDING REGION IN CEREBROSPINAL FLUID AND THE IDENTIFICATION OF A TARGET ENGAGEMENT BIOMARKER FOR THE NEW ANTI-TAU ANTIBODY E2814 AT ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC)2019 eisai.com ↗ The results confirmed that MTBR-containing tau species can be quantified in human CSF and there was a significant increase in MTBR in CSF of patients with AD (Caucasian aged between 64 and 84, MMSE: 13-26) in comparison with healthy adults (Caucasian aged between 46 and 75) (p<0.0001).

All press releases naming this drug 11 releases

Date	Issuer	Release
2026-07-14	Eisai Inc.	Eisai Presents Latest Findings Showed Etalanetug Reduced Alzheimer’s Disease Tau Tangle-Specific Plasma Biomarker MTBR-tau243 at Alzheimer’s Association International Conference® (AAIC®) 2026 Measuring the plasma eMTBR-tau243 biomarker may serve as a practical, less invasive method of capturing Alzheimer's disease-specific pathological changes and may play an important role in etalanetug’s future clinical development eisai.com ↗
2025-12-02	Eisai Inc.	Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025 Etalanetug demonstrated reduction of eMTBR-tau243, a novel CSF and plasma biomarker that specifically reflects tau tangle pathology, in phase Ib/II study eisai.com ↗
2025-09-17	Eisai Inc.	Anti-MTBR (microtubule binding region) Tau Antibody Etalanetug Granted FDA Fast Track Designation eisai.com ↗
2024-10-31	Eisai Inc.	EISAI PRESENTS LATEST CLINICAL FINDINGS SUGGESTING INHIBITION OF TAU PROPAGATION BY ANTI-MTBR TAU ANTIBODY E2814 AT THE 17TH CLINICAL TRIALS ON ALZHEIMER'S DISEASE CONFERENCE (CTAD) Eisai Initiates Phase II Clinical Study on Sporadic Early Alzheimer's Disease eisai.com ↗
2024-10-24	Eisai Inc.	EISAI TO PRESENT UPDATED DUAL-ACTING LECANEMAB DATA, RESEARCH ON BLOOD BIOMARKERS FOR PREDICTING PRESENCE OF AMYLOID IN THE BRAIN AND NEW FINDINGS ON THE ANTI-MTBR (MICROTUBULE BINDING REGION) TAU ANTIBODY E2814 AT THE 17TH CLINICAL TRIALS FOR ALZHEIMER'S eisai.com ↗
2023-07-12	Eisai Inc.	EISAI TO PRESENT THE LATEST ALZHEIMER’S DISEASE PIPELINE AND RESEARCH, INCLUDING LECANEMAB AND ANTI-MTBR TAU ANTIBODY E2814, AT THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2023 eisai.com ↗
2022-01-19	Eisai Inc.	FIRST SUBJECT ENROLLED IN PHASE II/III STUDY OF EISAI’S ANTI-MTBR TAU ANTIBODY E2814 FOR DOMINANTLY INHERITED ALZHEIMER'S DISEASE (DIAD), CONDUCTED BY DIAN-TU EISAI’S ANTI-AMYLOID BETA PROTOFIBRIL ANTIBODY LECANEMAB SELECTED AS THE BACKGROUND THERAPY FOR THE TAU NEXGEN STUDY eisai.com ↗
2021-11-09	Eisai Inc.	DIAN-TU SELECTS LECANEMAB AS BACKGROUND ANTI-AMYLOID THERAPY IN CLINICAL TRIAL EVALUATING INVESTIGATIONAL THERAPY TARGETING TAU FOR DOMINANTLY INHERITED ALZHEIMER'S DISEASE Eisai’s anti-microtubule binding region (MTBR) tau antibody E2814 previously selected as the first investigational therapy among anti-tau drugs for the DIAN-TU Tau Next Generation trial eisai.com ↗
2021-03-16	Eisai Inc.	ANTI-MTBR (MICROTUBULE BINDING REGION) TAU ANTIBODY E2814 IS SELECTED ON CLINICAL STUDY FOR DOMINANTLY INHERITED ALZHEIMER'S DISEASE BY DIAN-TU eisai.com ↗
2019-07-19	Eisai Inc.	EISAI PRESENTS DATA SHOWING QUANTIFICATION OF TAU MICROTUBULE BINDING REGION IN CEREBROSPINAL FLUID AND THE IDENTIFICATION OF A TARGET ENGAGEMENT BIOMARKER FOR THE NEW ANTI-TAU ANTIBODY E2814 AT ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC)2019 eisai.com ↗
2018-12-06	Eisai Inc.	EISAI AND UCL COMMENCE PREPARATIONS FOR PHASE I CLINICAL STUDIES IN ALZHEIMER’S DISEASE FOR NOVEL ANTI-TAU ANTIBODY E2814 DISCOVERED THROUGH JOINT RESEARCH eisai.com ↗

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

Field	Value	Cited text
Known as	Etalanetug	“Etalanetug (E2814) is designed to delay the clinical progression of Alzheimer's disease (AD) by binding to the microtubule binding region (MTBR) of tau implicated in seeding...” PMID 41964075 ↗ Apr 2026
Known as	E2814	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01760005 ↗ 4 NCT04231513 ↗ NCT04971733 ↗ NCT06602258 ↗ NCT05269394 ↗
Modality	Monoclonal antibody	— CHEMBL6068452 ↗
Route	Intravenous	“Administered intravenously in a blinded fashion” NCT01760005 ↗